Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Conjugate or complex
Reexamination Certificate
1999-06-30
2003-04-01
Devi, S. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Conjugate or complex
C424S193100, C424S190100, C424S184100, C424S260100, C424S234100, C424S185100, C530S300000, C530S825000, C530S806000, C530S807000
Reexamination Certificate
active
06541007
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to a vaccine for
Pseudomonas aeruginosa,
and in particular to novel vaccine peptides.
REFERENCES
1. Irvin, R. T., “Attachment and colonization of
Pseudomonas aeruginosa
: Role of the surface structures”, in
Pseudomonas aeruginosa as an Opportunistic Pathogen,
(Campa, M., M. Bendinelli, and H. Friedman, Eds.), pp 19-42, Plenum Press, New York (1993).
2. Pier, G. B.,
J. Infect. Dis.
151:575-580 (1985).
3. Rivera, M. and Nicotra, M. B.,
Am. Rev. Respir. Dis.
126:833-836 (1982).
4. Todd, T. R. J., et al.,
Am. Rev. Respir. Dis.
140:1585-1589 (1989).
5. Irvin, R. T., et al.,
Infect. Immun.
57:3720-3726 (1989).
6. Lee, K. K., et al.,
Mol. Microbiol.
3:1493-1499 (1989).
7. Doig, P., et al.,
Infect. Immun.
55:1517-1522 (1987).
8. McEachran, D. and Irvin, R. T.,
Can. J. Microbiol.
31:563-569 (1985).
9. Irvin, R. T., et al.,
Microb. Ecol. Health Dis.
3:39-47 (1990).
10. Bradley, D. E.,
Genet. Res.
19:39-51 (1972).
11. Folkhard, W. F., et al.,
J. Mol. Biol.
149:79-93 (1981).
12. Paranchych, W., et al.,
Clin. Invest. Med.
9:113-118 (1986).
13. Paranchych, W., et al., “Expression, processing, and assembly of
Pseudomonas aeruginosa
N-methylphenylalanine pilin”, in
Pseudomonas: Biotransformations, Pathogenesis and Evolving Biotechnology,
(Sliver, S., et al., Eds.), pp 343-351, American Society for Microbiology, Washington, D.C. (1990).
14. Pasloske, B. L., et al.,
J. Bacteriol.
170:3738-3741 (1988).
15. Yu, L., et al.,
Infect. Immun.
62:5213-9 (1994).
16. Sheth, H. B., et al.,
Mol. Microbiol.
11:715-23 (1994).
17. Doig, P., et al.,
Infect. Immun.
58:124-130 (1990).
18. Lee, K. K.,
Infect. Immun.
57:520-526 (1989).
19. Sheth, H. B., et al.,
Biomed. Pept. Proteins and Nucleic Acids
1:141-148 (1995).
20. Hanessian, S., et al.,
Nature
(
London
) 229:209-210 (1971).
21. Jones, R. J., et al.,
Lancet
ii:401-403 (1978).
22. MacIntyre, S., et al.,
Infect. Immun.
52 (1986).
23. Pier, G. B. and Thomas, D. M.,
J. Infect. Dis.
148:206-213 (1983).
24. Cryz, S. J., et al.,
Antibiot. Chemother.
42:177-183 (1989).
25. Lam, J. S., , et al.,
Infect. Immun.
42:88-98 (1983).
26. Matthews-Greer, J. M. and Gilleland, Jr., H. E.,
J. Infect. Dis.
155:1281-1291 (1987).
27. Pier, G. B., et al.,
Science
249:537-540 (1990).
28. Holder, I. A. and Naglich, J. G.,
J. Trauma.
26:118-122 (1986).
29. Rotering, H. and Dorner, F.,
Antibiot. Chemother.
42:218-228 (1989).
30. Sezen, I. Y., et al.,
Zentralbl. Bakteriol. Hyg. I. Abt. Orig.
231:126-132 (1975).
31. Cryz, S. J., Jr., et al.,
Infect. Immun.
39:1072-1079 (1983).
32. Lydick, E., et al.,
J. Infect. Dis.
151:375 (1985).
33. Finke, M., et al.,
Infect. Immun.
59:1251-1254 (1991).
34. Taussig, M. J., “Antigenic competition”, in
The Antigens
(Sela, M., Ed.), pp 333-368, Academic Press, New York (1977).
35. Hunt, J. D., et al.,
Vaccine
13:1649-1657 (1995).
36. Hunt, J. D., et al.,
Immunol. Cell Biol.
74:81-89 (1996).
37. Campbell, A. P., et al.,
Biochemistry
34:16255-16268 (1995).
38. Campbell, A. P., et al.,
J. Mol. Biol.
267:382-402 (1997).
39. McInnes, C., et al.,
Biochemistry
32:13432-40 (1993).
40. Rudner, X. L., et al.,
Invest. Ophthalmol. Vis. Sci.
33:2185-93 (1992).
41. Lee, K.K., et al.,
Infect. Immun.
58:2727-2732 (1990).
42. Wong, W. Y., Ph.D. Thesis: “Synthetic Peptide Approaches to Study the Adherence Binding Domain of the Pilin Protein of
Pseudomonas aeruginosa
Strain PAK,” University of Alberta, Edmonton, Alberta, Canada, p. 222 (1994).
43. Wong, W. Y., et al., “Pseudomonas Pilin Vaccine,” in The 8th Annual North American Cystic Fibrosis Conference, Orlando, Fla. (1994).
44. Wong, W. Y., et al.,
Protein Sci.
1:1308-18 (1992).
45. Campbell, A. P., et al.,
Int. J. Pept. Protein Res.
48:539-552 (1996).
46. Wong, W. Y., et al.,
Biochemistry
34:12963-12972 (1995).
47. Paranchych, W., et al.,
Can. J. Microbiol.
25:1175-1181 (1979).
48. Erickson, B. W. and Merrifield, R. B., “Solid-phase peptide synthesis”, in The Proteins, (Neurath, H. and R. L. Hill, Eds.), pp 255-527, Academic Press, New York (1976).
49. Nieto, A., et al.,
Mol. Immunol.
21:537-543 (1984).
BACKGROUND OF THE INVENTION
Pseudomonas aeruginosa
is a serious opportunistic gram-negative bacterial pathogen which can cause fatal infections in immunocompromised and immunosuppressed patients [1-4]. The first step in the infection process is the attachment to the host cell. This attachment is mediated by pili on the surface of the bacterium [2, 5, 6].
P. aeruginosa
uses several adhesins to mediate attachment to mucosal surfaces, but analysis of the binding properties of the adhesins [1, 7, 8] and binding competition studies [9] indicate that the pilus is the dominant adhesin responsible for initiating infections [1].
P. aeruginosa
pili are polarly located, with a structure resembling a hollow tube of 5.2 nm in outer diameter, 1.2 nm in central channel diameter, and an average length of 2.5 &mgr;m [10-12]. The pilus of
P. aeruginosa
is composed of multiple copies of a 13-17 kDa monomeric protein subunit called pilin. The C-terminal region of the pilin monomer contains the epithelial cell binding domain [5, 12] and is semiconserved in seven different strains of this bacterium [13, 14]. This semiconserved region has also been shown to bind to a minimal structural carbohydrate receptor sequence, &bgr;-GalNAc(1-4)&bgr;Gal, found in glycosphingolipids, specifically asialo-GM1 and asialo-GM2 [15, 16]. Furthermore, the C-terminal disulfide-bridged 17-residue region of the PAK pilin is known to be important in raising antibodies that block binding of both bacteria or their pili to epithelial cells [6, 17, 18]. Both monoclonal antisera generated from
P. aeruginosa
pili or polyclonal antisera generated from synthetic peptides representing the receptor binding domain of the pathogen have been shown to be efficacious in preventing infection [19].
Different types of
Pseudomonas aeruginosa
immunogens have been tried or are under development as vaccines. These include lipopolysaccharides [20-22], polysaccharide [23], polysaccharide conjugate [24], outer-membrane protein [25, 26], mucoid exopolysaccharide [27], flagella [28, 29], protease [30], elastase [31], exotoxin A [31, 32], and lipoprotein I [33]. An alternate to these approaches to vaccination against
P. aeruginosa
could employ a multivalent pili vaccine. However, a potential problem exists in this approach: inhibition of the immune response to one antigen or determinant by the administration of another antigen or determinant. This phenomenon, termed antigenic competition [34], leads to the reduction of antibody production and has been shown to occur between chemically related and unrelated antigens and also between associated and non-associated antigenic determinants. An example of this type of competition has been reported by Hunt and coworkers [35, 36] in the development of a multivalent pili vaccine against ovine footrot. In this case, antigenic competition occurs between the nine pili serotypes of the bacterium
Dichelobacter nodosus
that are required in a vaccine for complete protection against the disease. These results suggested that a cocktail or multicomponent vaccine composed of synthetic peptide immunogens representing the known strains of
Pseudomonas aeruginosa
pili may be problematic.
SUMMARY OF THE INVENTION
The invention includes a peptide vaccine for immunizing or treating a patient for infection by a
Pseudomonas aeruginosa
(PA) infection. The invention comprises (i) the peptide identified as SEQ ID NOS. 3-6; and (ii) a carrier protein conjugated to the peptide.
The peptide vaccine is useful in protecting a subject against Pseudomonas infection, by administering the vaccine to the subject, also in accordance with the invention.
In another aspect, the invention incl
Cachia Paul J.
Hodges Robert S.
Irvin Randall T.
Bell Boyd & Lloyd LLC
Devi S.
The Governors of the University of Alberta
LandOfFree
Vaccine for Pseudomonas aeruginosa does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vaccine for Pseudomonas aeruginosa, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccine for Pseudomonas aeruginosa will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3066670